In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

Qiu N. Sun; Annette W. Fothergill; Dora I. McCarthy; Michael G. Rinaldi; John R. Graybill

doi:10.1128/AAC.46.5.1581-1582.2002

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

Qiu N. Sun, Annette W. Fothergill, Dora I. McCarthy, Michael G. Rinaldi, John R. Graybill

Pathology

Research output: Contribution to journal › Article › peer-review

274 Scopus citations

Abstract

In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis. The MICs of POS at which 50% and 90% of the isolates were inhibited were 0.25 and 4 μg/ml, respectively. POS was significantly more active than VRC and FLC and slightly more active than ITC. The results suggest that POS has significant potential for clinical development against the zygomycetes.

Original language	English (US)
Pages (from-to)	1581-1582
Number of pages	2
Journal	Antimicrobial agents and chemotherapy
Volume	46
Issue number	5
DOIs	https://doi.org/10.1128/AAC.46.5.1581-1582.2002
State	Published - 2002

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.46.5.1581-1582.2002

Cite this

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. / Sun, Qiu N.; Fothergill, Annette W.; McCarthy, Dora I.; Rinaldi, Michael G.; Graybill, John R.

In: Antimicrobial agents and chemotherapy, Vol. 46, No. 5, 2002, p. 1581-1582.

Research output: Contribution to journal › Article › peer-review

@article{e660ab4d57984c779dbc2e11a54ed47a,

title = "In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes",

abstract = "In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis. The MICs of POS at which 50% and 90% of the isolates were inhibited were 0.25 and 4 μg/ml, respectively. POS was significantly more active than VRC and FLC and slightly more active than ITC. The results suggest that POS has significant potential for clinical development against the zygomycetes.",

author = "Sun, {Qiu N.} and Fothergill, {Annette W.} and McCarthy, {Dora I.} and Rinaldi, {Michael G.} and Graybill, {John R.}",

year = "2002",

doi = "10.1128/AAC.46.5.1581-1582.2002",

language = "English (US)",

volume = "46",

pages = "1581--1582",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

TY - JOUR

T1 - In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

AU - Sun, Qiu N.

AU - Fothergill, Annette W.

AU - McCarthy, Dora I.

AU - Rinaldi, Michael G.

AU - Graybill, John R.

PY - 2002

Y1 - 2002

N2 - In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis. The MICs of POS at which 50% and 90% of the isolates were inhibited were 0.25 and 4 μg/ml, respectively. POS was significantly more active than VRC and FLC and slightly more active than ITC. The results suggest that POS has significant potential for clinical development against the zygomycetes.

AB - In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis. The MICs of POS at which 50% and 90% of the isolates were inhibited were 0.25 and 4 μg/ml, respectively. POS was significantly more active than VRC and FLC and slightly more active than ITC. The results suggest that POS has significant potential for clinical development against the zygomycetes.

UR - http://www.scopus.com/inward/record.url?scp=0036233027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036233027&partnerID=8YFLogxK

U2 - 10.1128/AAC.46.5.1581-1582.2002

DO - 10.1128/AAC.46.5.1581-1582.2002

M3 - Article

C2 - 11959605

AN - SCOPUS:0036233027

VL - 46

SP - 1581

EP - 1582

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this